The FTSE 100 just got a boost. It climbed higher as investors smiled over good news from the US and China. These two big economies are showing signs of working together again. That gave markets around the world a push.
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
On August 13, Bullish Stock Soars in a dazzling debut on the NYSE, delivering a whopping 90 per cent gain by closing at $70, and pushing its valuation to roughly $10 billion. This debut marks one of the standout crypto exchange IPO surges, reflecting renewed investor appetite for digital asset platforms. Continue Reading on Meyka…
The FTSE 100 is often a go‑to for income seekers because many of its members pay robust dividends. Roughly speaking, the average FTSE 100 dividend yield sits around 3.5–4%, notably higher than many global indexes. But one high‑yielding component has recently slid about 15%, making investors wonder: Is this Passive Income Gem worth buying today? Continue Reading…
Raspberry Pi has reported a mixed first half, with profits slipping even as demand for its single-board computers shows fresh strength. The company’s latest results, the first annual update since its IPO, surprised some investors by combining a fall in H1 earnings with rising orders from education, hobbyists, and industrial IoT customers. Continue Reading on…
In recent months, UK borrowing has surged to the highest level since the peak of the pandemic, driven by rising interest costs, inflation-linked benefits, and sluggish tax growth. This sharp increase in government borrowing raises serious questions about fiscal sustainability, impacts on public services, and the broader economic outlook. Continue Reading on Meyka This article…
FTSE 250 attracts attention with a bold claim from an activist fund. They predict one of its dividend stocks will double in value in 3 years. Explores what this means for investors in the UK and beyond. Continue Reading on Meyka This article is available in full on our main platform. Get access to complete analysis,…
GlaxoSmithKline, widely known as GSK, recently reported a robust first half of 2025, with strong performance in its specialty medicines division and a bold forecast upgrade. Yet, paradoxically, the GSK share price remains weak, down around 16% from its year-high, despite evidence pointing to deep undervaluation. Continue Reading on Meyka This article is available in…